Trial · NCT06705478
Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV
NCT06705478, Phase 2, Suspended, National Institute of Allergy and Infectious Diseases (NIAID)
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV. Trials, record NCT06705478. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06705478
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV
- NCT number
- NCT06705478
- Status
- Suspended
- Phases
- Phase 2
- Enrollment
- 186 participants, estimated
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Conditions
- Major Depressive Disorder, Mild Neurocognitive Disorder, HIV
- Interventions
- Pramipexole ER, Escitalopram
- First posted
- 2024-11-26
- Last updated
- 2026-07-14
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Beck Depression Inventory-II (BDI-II/BDI-2) total score defined as the sum of all symptom scores | Baseline, Week 24 | |
| Primary | Occurrence of Grade ≥3 Adverse Events (AEs) or Grade ≥2 neuropsychiatric AEs related to study treatment | From study treatment administration through Week 24 | |
| Primary | Occurrence of Grade ≥2 neuropsychiatric AEs related to study treatment | From study treatment administration through Week 24 | |
| Secondary | Change in major depressive disorder (MDD) caseness, defined as the number of symptoms present from 0 to 9, of the symptoms of major depressive disorder | Baseline, Week 24 | |
| Secondary | Complete remission of the major depressive episode defined as a score of 0 on all of the 9 symptoms | Baseline, Week 24 | |
| Secondary | Change in neuropsychological (NP) z-score as assessed through 4 composite domain scores | Baseline, Week 24 | Each domain score is calculated as the average of the z-scores from the tests within the domain: * Outcome Domain 1: Cognitive Efficiency (Color Trails 1 and 2) * Outcome Domain 2: Verbal Learning and Memory (HVLT-R Learning Trials 1-3 Total and HVLT-R Delayed Recall) * Outcome Domain 3: Motor Skills (Grooved Pegboard, Non-dominant hand) * Outcome Domain 4: Language (Category Fluency Test \[Animals\]) |
| Secondary | Change in the medical outcomes study (MOS)-HIV mental health functioning summary score defined by the MOS-HIV Users Manual | Baseline, Week 24 | |
| Secondary | Change in the MOS-HIV cognitive functioning subscale score defined by the MOS-HIV Users Manual | Baseline, Week 24 | |
| Secondary | Occurrence of Grade ≥3 AEs or Grade ≥2 neuropsychiatric AEs (regardless of judged relationship to study treatment) | From study treatment administration through Week 24 | |
| Secondary | Occurrence of Grade ≥2 neuropsychiatric AEs (regardless of judged relationship to study treatment) | From study treatment administration through Week 24 |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as |
|---|---|
| Category Fluency | Secondary outcome |
Source ConductCognition
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06705478
GET https://conductscience.org/api/trials/v1/NCT06705478/registered